ConductScience.org, home

Trial · NCT07392151

Reversal to Normoglycemia by Treating Prediabetes

NCT07392151, Phase 3, Not yet recruiting, Michael Mæng

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Reversal to Normoglycemia by Treating Prediabetes. Trials, record NCT07392151. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07392151

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Reversal to Normoglycemia by Treating Prediabetes
NCT number
NCT07392151
Status
Not yet recruiting
Phases
Phase 3
Enrollment
158 participants, estimated
Lead sponsor
Michael Mæng
Conditions
Prediabetes, Chronic Coronary Syndrome
Interventions
Intensified medical follow-up and glucose-lowering drugs, No intervention
First posted
2026-02-06
Last updated
2026-02-06

Source ClinicalTrials.gov

Registered outcomes35

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPresence of a composite of retinopathy, nephropathy, neuropathy, and MASLDBaseline
PrimaryIncidence of normoglycemia defined as HbA1c <39 mmol/mol1-year follow-up
SecondaryPresence of: Retinopathy, Nephropathy, Neuropathy, or MASLDBaseline
SecondaryPresence of a composite of retinopathy, nephropathy, and neuropathy.Baseline
SecondaryIncidence of normoglycemia defined as HbA1c <42 mmol/mol1-year follow-up
SecondaryChange in HbA1c1-year follow-up
SecondaryChange in eGFR1-year follow-up
SecondaryChange in cystatin-C1-year follow-up
SecondaryChange in hs-CRP1-year follow-up
SecondaryChange in lipid parameters1-year follow-up

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07392151

GET https://conductscience.org/api/trials/v1/NCT07392151/registered?page=2